Korro Bio
Signal active
Organization
Contact Information
Overview
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.
Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues.
In 2018,
About
Industries
Biotechnology, Health Care, Pharmaceutical
Founded
2018
Employees
51-100
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Korro Bio headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $13.3B in funding across 48 round(s). With a team of 51-100 employees, Korro Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Korro Bio, raised $70.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
6
Lead Investors
0
Total Funding Amount
$277.5M
Details
3
Korro Bio has raised a total of $277.5M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Early Stage Venture | 91.5M | ||
| 2018 | Seed | |||
| 2022 | Early Stage Venture | 116.0M |
Investors
Korro Bio is funded by 42 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Deep Track Capital | - | FUNDING ROUND - Deep Track Capital | 70.0M |
| Tri Locum Partners | - | FUNDING ROUND - Tri Locum Partners | 70.0M |
| Korro Bio | - | FUNDING ROUND - Korro Bio | 70.0M |
| New Enterprise Associates | - | FUNDING ROUND - New Enterprise Associates | 70.0M |
Recent Activity
There is no recent news or activity for this profile.